The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

((SL Advertiser)) V-Juv offers up a simple solution for men and women who suffer from incontinence. No more diapers! call ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Treatment with vibegron reduced the ... approval of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for BPH, which underscores our urgency to ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

OAB can significantly impact quality of life; it can impact physical functioning, sexual function and social interactions. The standard treatments for overactive bladder include lifestyle changes ...

2024 /EINPresswire / -- The global overactive bladder (OAB) treatment market is experiencing remarkable growth, fueled by rising awareness, increasing prevalence of the condition, and demographic ...